A Phase II, Multicenter Study of Oral cMET Inhibitor INC280 in Adult Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC)
Phase of Trial: Phase II
Latest Information Update: 03 Aug 2017
At a glance
- Drugs Capmatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals Corporation
- 29 May 2017 Planned primary completion date changed from 28 Jan 2020 to 4 Sep 2018.
- 24 Apr 2017 Planned End Date changed from 20 Dec 2019 to 28 Jan 2020.
- 24 Apr 2017 Planned primary completion date changed from 20 Dec 2019 to 28 Jan 2020.